Terug
Ook genoteerd als
ALBHF
OTC
Dagbereik
€ 15,32
€ 15,50
52-Weeksbereik
€ 8,95
€ 19,45
Volume
500
50D / 200D Gem.
€ 15,86
/
€ 14,68
Vorige Slotkoers
€ 15,50
Quick Summary
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 8,7 | 0,3 |
| P/B | 0,8 | 3,0 |
| ROE % | 9,3 | 3,7 |
| Net Margin % | 4,7 | 3,8 |
| Rev Growth 5Y % | 18,5 | 10,0 |
| D/E | 0,0 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 |
€ 0,00
€ 0,00 – € 0,00
|
39,50B | 0 |
| FY2026 |
€ 0,00
€ 0,00 – € 0,00
|
35,24B | 0 |
No quarterly estimates available
Dividend History
Yield
0,00%
Payout Ratio
N/A
Growth (3Y)
N/A
Growth (5Y)
N/A
No dividend history available.
Belangrijkste Punten
Revenue grew 18,50% annually over 5 years — strong growth
Earnings grew 62,14% over the past year
Debt/Equity of 0,00 — conservative balance sheet
Generating 1,38B in free cash flow
P/E of 8,72 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 5,28%
Groei
Revenue Growth (5Y)
18,50%
Revenue (1Y)13,22%
Earnings (1Y)62,14%
FCF Growth (3Y)134,58%
Kwaliteit
Return on Equity
9,28%
ROIC7,23%
Net Margin4,68%
Op. Margin5,15%
Veiligheid
Debt / Equity
0,00
Current Ratio2,59
Interest Coverage604,09
Waardering
P/E Ratio
8,72
Forward P/EN/A
P/B Ratio0,77
EV/EBITDA6,54
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 13,22% | Revenue Growth (3Y) | 6,93% |
| Earnings Growth (1Y) | 62,14% | Earnings Growth (3Y) | 63,53% |
| Revenue Growth (5Y) | 18,50% | Earnings Growth (5Y) | 42,38% |
| Profitability | |||
| Revenue (TTM) | 30,60B | Net Income (TTM) | 1,43B |
| ROE | 9,28% | ROA | 6,76% |
| Gross Margin | 24,29% | Operating Margin | 5,15% |
| Net Margin | 4,68% | Free Cash Flow (TTM) | 1,38B |
| ROIC | 7,23% | FCF Growth (3Y) | 134,58% |
| Safety | |||
| Debt / Equity | 0,00 | Current Ratio | 2,59 |
| Interest Coverage | 604,09 | ||
| Dividends | |||
| Dividend Yield | 0,00% | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 8,72 | Forward P/E | N/A |
| P/B Ratio | 0,77 | P/S Ratio | 0,41 |
| PEG Ratio | 1,16 | Forward PEG | N/A |
| EV/EBITDA | 6,54 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 11,01% | ||
| Market Cap | 12,50B | Enterprise Value | 10,31B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 30,60B | 27,03B | 26,76B | 20,58B | 15,52B |
| Net Income | 1,43B | 883,48M | 535,65M | -265,56M | 348,59M |
| EPS (Diluted) | 1,78 | 1,25 | 0,79 | -0,39 | 0,52 |
| Gross Profit | 7,43B | 5,90B | 5,70B | 4,11B | 3,62B |
| Operating Income | 1,58B | 640,18M | -31,79M | -1,10B | 58,56M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 21,18B | 19,71B | 20,75B | 19,20B | 17,74B |
| Total Liabilities | 4,87B | 5,19B | 5,60B | 5,13B | 3,46B |
| Shareholders' Equity | 16,31B | 14,54B | 15,17B | 14,10B | 14,30B |
| Total Debt | 35,52M | 82,17M | 77,80M | 135,41M | 37,74M |
| Cash & Equivalents | 2,22B | 3,49B | 10,92B | 10,55B | 11,64B |
| Current Assets | 12,28B | 13,51B | 14,91B | 13,57B | 14,20B |
| Current Liabilities | 4,74B | 5,03B | 5,44B | 4,82B | 3,40B |
Strategiescores
This stock passed the criteria for 3 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026